New Drug Treatment Before Surgery for HER2-Positive Breast Cancer
Treatments studied
Part of Cancer, Skin clinical trials.
This trial tests a new drug called trastuzumab rezetecan given before surgery for early-stage HER2-positive breast cancer. It's designed for patients whose cancer doesn't respond well to standard HER2-targeted treatments.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Age 18 or older; if you can become pregnant, you must have a negative pregnancy test and use effective birth control during treatment
- Diagnosed with stage II or III invasive breast cancer (early stage, not spread to distant organs) that is HER2-positive
- Have not received any chemotherapy, immunotherapy, hormonal therapy, or breast cancer surgery before
- In good overall health (able to carry out most daily activities) with normal blood counts and organ function
- No serious heart problems and a normal heart pumping ability (ejection fraction ≥55%)
- No difficulty swallowing and able to complete all required baseline tests
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new antibody-drug combination (trastuzumab rezetecan, also called T-DXd) for patients with HER2-positive breast cancer whose tumor did not fully disappear after initial chemotherapy. The goal is to see if this drug can reduce the risk of cancer coming back.
This trial tests a new targeted drug (BL-M07D1) with or without another drug called pertuzumab, compared to a standard chemotherapy plus two targeted drugs, before surgery for HER2-positive breast cancer. The goal is to see if the new combination works better at shrinking tumors before surgery.
This trial tests whether a less intense treatment before surgery works as well as the standard approach for early-stage HER2-positive breast cancer. It aims to reduce side effects while still being effective.
This trial tests a combination of two drugs, trastuzumab deruxtecan (SHR-A1811) and pertuzumab, given before surgery to shrink HER2-positive breast cancer. It is for women with stage II or III breast cancer who have not yet had treatment and are in good overall health.
This trial tests a new combination of drugs for people with HER2-positive early breast cancer whose tumors did not respond well to the first round of standard targeted therapy plus chemo. The goal is to see if switching to trastuzumab-rezetecan plus pertuzumab or a different chemo combo (nab-paclitaxel, carboplatin, trastuzumab, and pyrotinib) can shrink the tumor before surgery.
This trial tests a combination of targeted drugs and chemotherapy before surgery for HER2-positive breast cancer. It aims to see if this approach can shrink or eliminate the tumor, making surgery more effective.
Hear when a new HER2-positive Breast Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.